References
- World Health Organization . Schistosomiasis: number of people treated in 2011. Wkly Epidemiol. Rec.88 (8), 81–88 (2013).
- Rollinson D , KnoppS, LevitzSet al. Time to set the agenda for schistosomiasis elimination. Acta Trop.128 (2), 423–440 (2013).
- Njenga SM , MutungiFM, WamaeCN, MwanjeMT, NjiruKK, BockarieMJ. Once a year school-based deworming with praziquantel and albendazole combination may not be adequate for control of urogenital schistosomiasis and hookworm infection in Matuga District, Kwale County, Kenya. Parasit. Vectors.7, 74 (2014).
- Lelo AE , MburuDN, MagomaGNet al. No apparent reduction in schistosome burden or genetic diversity following four years of school-based mass drug administration in Mwea, central Kenya, a heavy transmission area. PLoS Negl. Trop. Dis.8 (10), e3221 (2014).
- Ross AG , OlvedaRM, ChyDet al. Can mass drug administration lead to the sustainable control of schistosomiasis? J. Infect. Dis. 211 (2), 283–289 (2015).
- Won KY , AbudhoB, BlackstockAJet al. Assessment of quality of life as a tool for measuring morbidity due to Schistosoma mansoni infection and the impact of treatment. Am. J. Trop. Med. Hyg.90 (2), 322–328 (2014).
- Omedo MO , MateyEJ, AwitiAet al. Community health workers’ experiences and perspectives on mass drug administration for schistosomiasis control in western Kenya: the SCORE Project. Am. J. Trop. Med. Hyg.87 (6), 1065–1072 (2012).
- Olliaro P , Delgado-RomeroP, KeiserJ. The little we know about the pharmacokinetics and pharmacodynamics of praziquantel (racemate and R-enantiomer). J. Antimicrob. Chemother.69 (4), 863–870 (2014).
- Meister I , Ingram-SieberK, CowanNet al. Activity of praziquantel enantiomers and main metabolites against Schistosoma mansoni. Antimicrob. Agents. Chemother.58 (9), 5466–5472 (2014).
- Valentim CL , CioliD, ChevalierFDet al. Genetic and molecular basis of drug resistance and species-specific drug action in schistosome parasites. Science342 (6164), 1385–1389 (2013).
- Guglielmo S , CorteseD, VotteroFet al. New praziquantel derivatives containing NO-donor furoxans and related furazans as active agents against Schistosoma mansoni. Eur. J. Med. Chem.84, 135–145 (2014).
- Secor WE . Water-based interventions for schistosomiasis control. Pathog. Glob. Health108 (5), 246–254 (2014).
- Keiser J , SiluéKD, AdiossanLKet al. Praziquantel, mefloquine-praziquantel, and mefloquine-artesunate-praziquantel against Schistosoma haematobium: a randomized, exploratory, open-label trial. PLoS Negl. Trop. Dis.8 (7), e2975 (2014).
- King CH , OlbrychSK, SoonM, SingerME, CarterJ, ColleyDG. Utility of repeated praziquantel dosing in the treatment of schistosomiasis in high-risk communities in Africa: a systematic review. PLoS Negl. Trop. Dis.5 (9), e1321 (2011).
- Tukahebwa EM , VennervaldBJ, NuwahaF, KabatereineNB, MagnussenP. Comparative efficacy of one versus two doses of praziquantel on cure rate of Schistosoma mansoni infection and re-infection in Mayuge District, Uganda. Trans. R. Soc. Trop. Med. Hyg.107 (6), 397–404 (2013).
- Garba A , LamineMS, BarkiréNet al. Efficacy and safety of two closely spaced doses of praziquantel against Schistosoma haematobium and S. mansoni and re-infection patterns in school-aged children in Niger. Acta Trop.128 (2), 334–344 (2013).
- Ndeffo Mbah ML , GilbertJA, GalvaniAP. Evaluating the potential impact of mass praziquantel administration for HIV prevention in Schistosoma haematobium high-risk communities. Epidemics7, 22–27 (2014).
- Ndeffo Mbah ML , SkripL, GreenhalghS, HotezP, GalvaniAP. Impact of Schistosoma mansoni on malaria transmission in Sub-Saharan Africa. PLoS Negl. Trop. Dis.8 (10), e3234 (2014).
- Knopp S , MohammedKA, AliSMet al. Study and implementation of urogenital schistosomiasis elimination in Zanzibar (Unguja and Pemba islands) using an integrated multidisciplinary approach. BMC Public Health12, 930 (2012).
- What influences open defecation and latrine ownership in rural households: findings from a global review. www.wsp.org